Bonds offering 4% yields are losing their purchasing power when real inflation is somewhere between 6% to 12%, according to celebrated economist #Gloom #Boom #Doom #author #recommends #buying #gold #bitcoin
Immunovant stock hits 52-week high at $27.71 #Immunovant #stock #hits #52week #high
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser. #Client #Challenge
Oklo inked an agreement with the Department of Energy, which will help the company in its plans to produce medical and research radioisotopes. Oklo is advancing a power project with Meta to support its data centers in Ohio. Only investorswith high tolerances for risk should consider positions in Oklo at this time. 10 stocks we … Read more
March NY world sugar #11 (SBH26) today is up +0.08 (+0.53%). March London ICE white sugar #5 (SWH26) is up +2.00 (+0.47%). Sugar prices today extended this week’s gains and posted 1-week highs. Expectations of index-related buying of sugar futures for the annual rebalancing of commodity indexes are pushing sugar prices higher today. Citigroup projects … Read more
Things are already hard for America’s seniors. In less than a decade, they’ll sink even further. #Social #Security #crisis #leave #U.S #retirees #worse #poorer #countries #Ecuador #Poland
Andreessen Horowitz raises $15 billion across five funds for tech startup investments #Andreessen #Horowitz #raises #billion #funds #tech #startup #investments
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser. #Client #Challenge
Market Digest: LNT, STZ, RDDT, HOOD #Market #Digest #LNT #STZ #RDDT #HOOD
(RTTNews) – Kezar Life Sciences (KZR) said the FDA Division of Hepatology and Nutrition has granted the company a Type C meeting for the first quarter to discuss the development of zetomipzomib, a selective inhibitor of the immunoproteasome, in patients with autoimmune hepatitis. The Type C meeting will involve review of a potential global, randomized … Read more